Get access

Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial

Authors

Errata

This article is corrected by:

  1. Errata: Erratum Volume 7, Issue 3, 321, Article first published online: 28 August 2011

  • Declaration of conflict of interest.

  • Mok SK T is a member of advisory boards of Roche and Eli Lilly and Merck Serono. The following received research funding from F. Hoffman-La Roche: T-C Hsia, V Sriuranpong, S Thongprasert (who also received research finding from Genentech), D Chua. N Moore is an employee of F. Hoffmann-La Roche AG. The authors do not report any conflict of interest with regard to the contents of this study other than those stated.

Dr Tony SK Mok MD, Prince of Wales Hospital, Hong Kong, Address: 30–32 Ngan Shing St, Shatin NT, Hong Kong. Email: tony@clo.cuhk.edu.hk

Abstract

Aim:  The phase III AVAiL study evaluated the efficacy and safety of the anti-vascular epidermal growth factor agent bevacizumab combined with platinum-based chemotherapy as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC). We report the results of a preplanned analysis of Asian patients enrolled in AVAiL.

Methods:  Patients with recurrent or advanced non-squamous NSCLC were randomized to receive bevacizumab 7.5 mg/kg, bevacizumab 15 mg/kg or placebo, plus cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles, followed by bevacizumab or placebo until disease progression. An exploratory analysis was undertaken to assess efficacy and safety in an Asian subgroup.

Results:  Of the 1043 patients enrolled, 105 were Asian and were included in the subgroup analysis. Progression-free survival was 8.5 months (95% CI 7.3–10.8) in the bevacizumab 15-mg/kg group, 8.2 (95% CI 6.6–11.7) in the 7.5-mg/kg group and 6.1 (95% CI 5.1–8.0) in the placebo group. Median overall survival in the 7.5-mg/kg bevacizumab group was prolonged compared with placebo group (HR 0.46; 95% CI 0.22–0.97). Nausea was the most common adverse event, occurring at similar rates (ranging from 69–76%) in all study groups. Hypertension was the most common adverse event of special interest, seen in 29, 55 and 16% of patients in the 7.5-mg/kg and 15-mg/kg bevacizumab and placebo groups, respectively.

Conclusion:  Study results strongly suggest that bevacizumab at a dose of 7.5 mg/kg improves the duration of overall survival when combined with cisplatin-gemcitabine in Asian patients. Bevacizumab was well tolerated in this patient group.

Ancillary